A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases.
<h4>Background</h4>Biologics are used for the treatment of inflammatory bowel diseases, Crohn´s disease and ulcerative colitis refractory to conventional treatment. In order to allocate healthcare spending efficiently, costly biologics for inflammatory bowel diseases are an important tar...
Main Authors: | Saara Huoponen, Marja Blom |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0145087&type=printable |
Similar Items
-
Frequency of use and cost of biologic treatment for inflammatory bowel disease and inflammatory bowel disease-associated arthropathy in Colombia in 2019
by: D.G. Fernández-Ávila, et al.
Published: (2024-04-01) -
Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
by: Heidi Taipale, et al.
Published: (2022-07-01) -
Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
by: Rita Lauro, et al.
Published: (2021-11-01) -
Review of the safety with biologics in inflammatory bowel disease
by: Andrea Pascual, et al.
Published: (2022-07-01) -
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
by: Bye, W, et al.
Published: (2017)